vs
Side-by-side financial comparison of EXELIXIS, INC. (EXEL) and Federal Realty Investment Trust (FRT). Click either name above to swap in a different company.
EXELIXIS, INC. is the larger business by last-quarter revenue ($598.7M vs $336.0M, roughly 1.8× Federal Realty Investment Trust). EXELIXIS, INC. runs the higher net margin — 40.8% vs 38.6%, a 2.2% gap on every dollar of revenue. On growth, Federal Realty Investment Trust posted the faster year-over-year revenue change (8.7% vs 5.6%). Over the past eight quarters, EXELIXIS, INC.'s revenue compounded faster (18.7% CAGR vs 6.5%).
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
Federal Realty Investment Trust is a real estate investment trust that invests in shopping centers in the Northeastern United States, the Mid-Atlantic states, California, and South Florida.
EXEL vs FRT — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $598.7M | $336.0M |
| Net Profit | $244.5M | $129.7M |
| Gross Margin | 95.6% | — |
| Operating Margin | 39.3% | 53.8% |
| Net Margin | 40.8% | 38.6% |
| Revenue YoY | 5.6% | 8.7% |
| Net Profit YoY | 74.8% | 103.5% |
| EPS (diluted) | $0.89 | $1.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $598.7M | $336.0M | ||
| Q4 25 | $597.8M | $336.0M | ||
| Q3 25 | $568.3M | $322.3M | ||
| Q2 25 | $555.4M | $311.5M | ||
| Q1 25 | $566.8M | $309.2M | ||
| Q4 24 | — | $311.4M | ||
| Q3 24 | $539.5M | $303.6M | ||
| Q2 24 | $637.2M | $296.1M |
| Q1 26 | $244.5M | $129.7M | ||
| Q4 25 | $193.6M | $129.7M | ||
| Q3 25 | $184.8M | $61.6M | ||
| Q2 25 | $159.6M | $155.9M | ||
| Q1 25 | $139.9M | $63.8M | ||
| Q4 24 | — | $65.5M | ||
| Q3 24 | $118.0M | $61.0M | ||
| Q2 24 | $226.1M | $112.0M |
| Q1 26 | 95.6% | — | ||
| Q4 25 | 96.9% | — | ||
| Q3 25 | 96.6% | — | ||
| Q2 25 | 96.5% | — | ||
| Q1 25 | 96.5% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 96.8% | — | ||
| Q2 24 | 97.2% | — |
| Q1 26 | 39.3% | 53.8% | ||
| Q4 25 | 39.6% | 53.8% | ||
| Q3 25 | 37.6% | 34.3% | ||
| Q2 25 | 33.6% | 65.1% | ||
| Q1 25 | 28.8% | 35.0% | ||
| Q4 24 | — | 35.1% | ||
| Q3 24 | 25.2% | 34.9% | ||
| Q2 24 | 43.3% | 53.0% |
| Q1 26 | 40.8% | 38.6% | ||
| Q4 25 | 32.4% | 38.6% | ||
| Q3 25 | 32.5% | 19.1% | ||
| Q2 25 | 28.7% | 50.0% | ||
| Q1 25 | 24.7% | 20.6% | ||
| Q4 24 | — | 21.0% | ||
| Q3 24 | 21.9% | 20.1% | ||
| Q2 24 | 35.5% | 37.8% |
| Q1 26 | $0.89 | $1.49 | ||
| Q4 25 | $0.69 | $1.49 | ||
| Q3 25 | $0.65 | $0.69 | ||
| Q2 25 | $0.55 | $1.78 | ||
| Q1 25 | $0.47 | $0.72 | ||
| Q4 24 | — | $0.74 | ||
| Q3 24 | $0.40 | $0.70 | ||
| Q2 24 | $0.77 | $1.32 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | $107.4M |
| Total DebtLower is stronger | — | $5.0B |
| Stockholders' EquityBook value | $2.2B | $3.2B |
| Total Assets | $2.8B | $9.1B |
| Debt / EquityLower = less leverage | — | 1.53× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.1B | $107.4M | ||
| Q4 25 | $988.5M | $107.4M | ||
| Q3 25 | $791.1M | $111.3M | ||
| Q2 25 | $1.0B | $177.0M | ||
| Q1 25 | $1.1B | $109.2M | ||
| Q4 24 | — | $123.4M | ||
| Q3 24 | $1.2B | $97.0M | ||
| Q2 24 | $1.0B | $103.2M |
| Q1 26 | — | $5.0B | ||
| Q4 25 | — | $5.0B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $4.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $2.2B | $3.2B | ||
| Q4 25 | $2.2B | $3.2B | ||
| Q3 25 | $2.0B | $3.2B | ||
| Q2 25 | $2.1B | $3.2B | ||
| Q1 25 | $2.2B | $3.2B | ||
| Q4 24 | — | $3.2B | ||
| Q3 24 | $2.3B | $3.1B | ||
| Q2 24 | $2.1B | $3.0B |
| Q1 26 | $2.8B | $9.1B | ||
| Q4 25 | $2.8B | $9.1B | ||
| Q3 25 | $2.7B | $8.9B | ||
| Q2 25 | $2.8B | $8.6B | ||
| Q1 25 | $2.9B | $8.6B | ||
| Q4 24 | — | $8.5B | ||
| Q3 24 | $3.0B | $8.5B | ||
| Q2 24 | $2.8B | $8.4B |
| Q1 26 | — | 1.53× | ||
| Q4 25 | — | 1.53× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.42× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $333.5M | — |
| Free Cash FlowOCF − Capex | $332.4M | — |
| FCF MarginFCF / Revenue | 55.5% | — |
| Capex IntensityCapex / Revenue | 0.2% | — |
| Cash ConversionOCF / Net Profit | 1.36× | — |
| TTM Free Cash FlowTrailing 4 quarters | $875.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $333.5M | — | ||
| Q4 25 | $290.3M | $622.4M | ||
| Q3 25 | $49.0M | $147.8M | ||
| Q2 25 | $211.4M | $150.7M | ||
| Q1 25 | $240.3M | $179.0M | ||
| Q4 24 | — | $574.6M | ||
| Q3 24 | $271.3M | $144.1M | ||
| Q2 24 | $119.5M | $169.7M |
| Q1 26 | $332.4M | — | ||
| Q4 25 | $288.8M | — | ||
| Q3 25 | $46.2M | — | ||
| Q2 25 | $208.5M | — | ||
| Q1 25 | $236.3M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $263.1M | — | ||
| Q2 24 | $113.0M | — |
| Q1 26 | 55.5% | — | ||
| Q4 25 | 48.3% | — | ||
| Q3 25 | 8.1% | — | ||
| Q2 25 | 37.5% | — | ||
| Q1 25 | 41.7% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 48.8% | — | ||
| Q2 24 | 17.7% | — |
| Q1 26 | 0.2% | — | ||
| Q4 25 | 0.2% | — | ||
| Q3 25 | 0.5% | — | ||
| Q2 25 | 0.5% | — | ||
| Q1 25 | 0.7% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.5% | — | ||
| Q2 24 | 1.0% | — |
| Q1 26 | 1.36× | — | ||
| Q4 25 | 1.50× | 4.80× | ||
| Q3 25 | 0.27× | 2.40× | ||
| Q2 25 | 1.32× | 0.97× | ||
| Q1 25 | 1.72× | 2.81× | ||
| Q4 24 | — | 8.77× | ||
| Q3 24 | 2.30× | 2.36× | ||
| Q2 24 | 0.53× | 1.52× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EXEL
| Cabometyx | $544.7M | 91% |
| Collaboration | $52.1M | 9% |
| Collaborative Arrangementwith Takeda | $5.9M | 1% |
| Cometriq | $1.8M | 0% |
FRT
Segment breakdown not available.
